| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/21645515.2017.1349584 |
| P8608 | Fatcat ID | release_nqz5fiwsrffajfehoajumbxfiy |
| P932 | PMC publication ID | 5718833 |
| P698 | PubMed publication ID | 28825870 |
| P50 | author | Ravendra Garg | Q83904749 |
| P2093 | author name string | S van Drunen Littel-van den Hurk | |
| A Potter | |||
| L Latimer | |||
| V Gerdts | |||
| P2860 | cites work | Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection | Q45398592 |
| Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection | Q45404243 | ||
| Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus | Q45564955 | ||
| Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines | Q45849052 | ||
| Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice | Q45868048 | ||
| The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. | Q46018304 | ||
| Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group | Q77300551 | ||
| A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models | Q27312129 | ||
| Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 | ||
| Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection | Q30433900 | ||
| Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. | Q31170493 | ||
| Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model | Q33901537 | ||
| Respiratory syncytial virus and parainfluenza virus | Q33952428 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease | Q34330690 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Biological challenges and technological opportunities for respiratory syncytial virus vaccine development | Q34504791 | ||
| Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. | Q34624625 | ||
| Immunological mechanisms of vaccination | Q35659533 | ||
| CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells | Q35971414 | ||
| Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains | Q36363325 | ||
| Viral and host factors in human respiratory syncytial virus pathogenesis | Q36483836 | ||
| Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward. | Q37110057 | ||
| Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice | Q37222041 | ||
| Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant | Q37273249 | ||
| Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. | Q37404708 | ||
| A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. | Q37627348 | ||
| Multifunctional cationic host defence peptides and their clinical applications | Q37875767 | ||
| Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. | Q39328333 | ||
| Immunomodulatory activities of small host defense peptides | Q40430371 | ||
| A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus | Q40512544 | ||
| The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies | Q41511965 | ||
| Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. | Q42235080 | ||
| Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. | Q42261596 | ||
| Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection | Q44390775 | ||
| Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice | Q45367510 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P304 | page(s) | 2894-2901 | |
| P577 | publication date | 2017-08-21 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus | |
| P478 | volume | 13 |
| Q91440678 | A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice |
| Q47137438 | Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens |
| Q55534670 | Respiratory Syncytial Virus Vaccine Approaches: a Current Overview. |
Search more.